Literature DB >> 23174221

Beta-catenin signaling induces CYP1A1 expression by disrupting adherens junctions in Caco-2 human colon carcinoma cells.

Shuya Kasai1, Takanori Ishigaki, Ryo Takumi, Toru Kamimura, Hideaki Kikuchi.   

Abstract

BACKGROUND: The aryl hydrocarbon (Ah) receptor is one of the best known ligand-activated transcription factors. The present study has focused on the wound-healing process on Ah receptor function.
METHODS: Depletion of calcium from culture medium of Caco-2 human colon carcinoma cells by transfer to Minimal Essential Medium (Spinner Modification; S-MEM) destroyed adherens junctions and the cells were used as the model of wound-healing process.
RESULTS: Calcium depletion induced both nuclear translocation of the Ah receptor, and increased expression of CYP1A1 and Slug mRNAs in Caco-2 cells. However, expression of Slug mRNA was not significantly induced by treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Knockdown of the Ah receptor and treatment with Ah receptor antagonists decreased level of CYP1A1 mRNA. The fragment of E-cadherin released by gamma-secretase was not involved in induction of CYP1A1 mRNA following S-MEM treatment. Knockdown of beta-catenin increased levels of Ah receptor mRNA, which may be attributable to direct or indirect involvement of beta-catenin in suppression of the Ah receptor gene.
CONCLUSIONS: Our results suggest that mRNA induction of some genes by destruction of adherens junctions depends on the Ah receptor. beta-Catenin, one of the components of the adherens junction, was released from the E-cadherin complex, which resulted in its increased interaction with the Ah receptor, and was translocated into the nucleus, and consequently the target genes would be transcribed. GENERAL SIGNIFICANCE: Our observations suggest that some aspects of the molecular mechanism of wound healing involve the Ah receptor.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23174221     DOI: 10.1016/j.bbagen.2012.11.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Expression profile of CYP1A1 and CYP1B1 enzymes in endometrial tumors.

Authors:  Ioannis Spyrou; Stavros Sifakis; Achilles Ploumidis; Alexandros E Papalampros; Evangellos Felekouras; Aristidis M Tsatsakis; Demetrios A Spandidos; Vasilis P Androutsopoulos
Journal:  Tumour Biol       Date:  2014-06-24

2.  Signal integration by the CYP1A1 promoter--a quantitative study.

Authors:  Pascal Schulthess; Alexandra Löffler; Silvia Vetter; Luisa Kreft; Michael Schwarz; Albert Braeuning; Nils Blüthgen
Journal:  Nucleic Acids Res       Date:  2015-05-01       Impact factor: 16.971

3.  Expression profile of CYP1A1 and CYP1B1 enzymes in colon and bladder tumors.

Authors:  Vasilis P Androutsopoulos; Ioannis Spyrou; Achilles Ploumidis; Alexandros Eystathios Papalampros; Michalis Kyriakakis; Demetrios Delakas; Demetrios A Spandidos; Aristidis M Tsatsakis
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

4.  Interleukin-6 mediated upregulation of CYP1B1 and CYP2E1 in colorectal cancer involves DNA methylation, miR27b and STAT3.

Authors:  S A A Patel; U Bhambra; M P Charalambous; R M David; R J Edwards; T Lightfoot; A R Boobis; N J Gooderham
Journal:  Br J Cancer       Date:  2014-10-21       Impact factor: 7.640

Review 5.  Environmental Ligands of the Aryl Hydrocarbon Receptor and Their Effects in Models of Adult Liver Progenitor Cells.

Authors:  Jan Vondráček; Miroslav Machala
Journal:  Stem Cells Int       Date:  2016-05-04       Impact factor: 5.443

Review 6.  Regulation of Intestinal Stem Cell Stemness by the Aryl Hydrocarbon Receptor and Its Ligands.

Authors:  Paul J Wisniewski; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Front Immunol       Date:  2021-03-10       Impact factor: 7.561

7.  Insight into the relationship between aryl-hydrocarbon receptor and β-catenin in human colon cancer cells.

Authors:  Kazuhiro Shiizaki; Kenta Kido; Yasuhiro Mizuta
Journal:  PLoS One       Date:  2019-11-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.